Skip to main content

RBC Capital Remains a Buy on Surgery Partners (SGRY)

Tipranks - Tipranks - Thu Mar 5, 7:02AM CST

In a report released yesterday, Michael Dahl from RBC Capital maintained a Buy rating on Surgery Partners, with a price target of $20.00. The company’s shares closed yesterday at $13.92.

Claim 70% Off TipRanks Premium

Dahl covers the Consumer Cyclical sector, focusing on stocks such as Toll Brothers, Tri Pointe, and DR Horton. According to TipRanks, Dahl has an average return of 9.5% and a 60.45% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Surgery Partners with a $20.70 average price target, representing a 48.71% upside. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $17.50 price target.

See today’s best-performing stocks on TipRanks >>

Based on Surgery Partners’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $885 million and a GAAP net loss of $15 million. In comparison, last year the company earned a revenue of $864.4 million and had a GAAP net loss of $108.5 million

Read More on SGRY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).